We updated the design of this site on December 18, 2017. Learn more.
ClinicalTrials.gov Menu

Efficacy of MK0557 in Combination With Sibutramine or Orlistat (0557-015)(COMPLETED)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00533481
Recruitment Status : Completed
First Posted : September 21, 2007
Last Update Posted : September 16, 2016
Information provided by (Responsible Party):
Merck Sharp & Dohme Corp.

Brief Summary:
Study medicine will be given alone, or in combination with either sibutramine or orlistat, to obese subjects to compare the effect on body weight over a six month period.

Condition or disease Intervention/treatment Phase
Obesity Drug: MK0557 Phase 2

Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 497 participants
Allocation: Randomized
Intervention Model: Factorial Assignment
Masking: Double (Participant, Investigator)
Primary Purpose: Treatment
Study Start Date : February 2004
Primary Completion Date : December 2004
Study Completion Date : December 2004

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 65 Years   (Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Men and women between the ages of 18-65 who are considered obese (have a body mass index between 30 and 43)

Exclusion Criteria:

  • Subject has high blood pressure or is taking any high blood pressure medicine
  • History of psychiatric disorder, stroke, or heart disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT00533481

Sponsors and Collaborators
Merck Sharp & Dohme Corp.
Study Director: Medical Monitor Merck Sharp & Dohme Corp.

Responsible Party: Merck Sharp & Dohme Corp.
ClinicalTrials.gov Identifier: NCT00533481     History of Changes
Other Study ID Numbers: 0557-015
First Posted: September 21, 2007    Key Record Dates
Last Update Posted: September 16, 2016
Last Verified: September 2016